Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients.

Dulce M. Barrios M.S,Diana G. Wang,Victoria Susana Blinder,Jacqueline Bromberg,Pamela Drullinsky,Samuel Funt,Komal Jhaveri,Diana Lake,Tomas G. Lyons,Shanu Modi,Pedram Razavi,Michelle Sidel,Tiffany A. Traina,Linda T. Vahdat,Mario E. Lacouture

Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients.

2020

Dulce M. Barrios M.S
Diana G. Wang
Victoria Susana Blinder
Jacqueline Bromberg
Pamela Drullinsky
Samuel Funt
Komal Jhaveri
Diana Lake
Tomas G. Lyons
Shanu Modi
Pedram Razavi
Michelle Sidel
Tiffany A. Traina
Linda T. Vahdat
Mario E. Lacouture

1063Background: Rash develops in approximately 50% of breast cancer patients receiving alpelisib, often requiring dose modifications. Herein, we describe the characteristics of alpelisib-related de...

Keywords:

Physical therapy
Breast cancer
Internal medicine
Adverse effect
Medicine
Rash
Pathology
Dermatology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations